Skip to content

CLINICAL MANAGEMENT OF BRONCHIAL ASTHMA (SWASA KAASAM) USING SIDDHA HERBOMINERAL FORMULATION THALAGA KARUPPU

EFFICACY OF THAALAGA KARUPPU IN THE CLINICAL MANAGEMENT OF BRONCHIAL ASTHMA (SWASA KAASAM) - Nil

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2023/10/058873
Enrollment
10
Registered
2023-10-19
Start date
Unknown
Completion date
Unknown
Last updated
2023-11-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: J454- Moderate persistent asthma

Interventions

Intervention1: Internal Medicine: THAALAGA KARUPPU is a type of Chenduram administered for Bronchial asthma according Siddha literature. Control Intervention1: Nil: Nil

Sponsors

National Institute of Siddha
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Moderate persistent type of Bronchial Asthma Weekly twice or daily symptoms of difficulty in breathing Tightness of chest Wheeze - Added sound (Rhonchi) cough with or without expectoration FEV1/FVC reduced 5 percentage Previous history of bronchial asthma Night time wheezing more than one day/week Reversible by bronchodilators Patient who are willing to take radiological investigation and provide blood for lab investigation Patient who is willing to undergo Pulmonary Function Test

Exclusion criteria

Exclusion criteria: Restrictive lung disease Tuberculosis Lung Carcinoma and other Carcinomas Status asthmatics Pleural effusion Cardiac disease Renal disease Recent abdominal and thoracic surgery Recent hemoptysis Pneumothorax Recent history of abdominal thoracic or cerebral aneurysm Sleep apnea Pregnancy and Lactation

Design outcomes

Primary

MeasureTime frame
Primary outcome is assessed by comparing the lung volumes and capacities in pre and post treatment pulmonary function testTimepoint: 7 days medicine 7 days drug holiday the course repeated if need and follow up for 3 months

Secondary

MeasureTime frame
Relieving of other clinical symptoms Evaluating clinical lab parameters including Ig E AECTimepoint: 7 days medicine 7 days drug holiday the course repeated if need and follow up for 3 months

Countries

India

Contacts

Public ContactDr V Srinivasan

National Institute of Siddha

seenunis47@gmail.com9965962592

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026